Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1

Journal of Clinical Investigation

Volumn 105, Issue 6, 2000, Pages 711-719

  Accad, Michel ^a,b,c   Smith, Steven J ^a,c   Newland, Dale L ^a   Sanan, David A ^a   King Jr , Lloyd E ^d   Linton, MacRae F ^d   Fazio, Sergio ^d   Farese Jr , Robert V ^a,b,c  

^a GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL ACYLTRANSFERASE; ENZYME INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENZYME DEFICIENCY; FOAM CELL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XANTHOMATOSIS;

EID: 0034023061     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9021     Document Type: Article

References (34)

1. Suckling, K.E., and Stange, E.F. 1985. Role of acyl-CoA:cholesterol acyltransferase in cellular cholesterol metabolism. J. Lipid Res. 26:647-671.
2. Chang, T.Y., Chang, C.C.Y., and Cheng, D. 1997. Acyl-coenzyme A:cholosterol acyltransferase. Annu. Rev. Biochem. 66:613-638.
3. Chang, T.Y., Chang, C.C.Y., and Cadigan, K.M. 1994, The structure of acyl coenzyme A-cholesterol acyltransferase and its potential relevance to atherosclerosis. Trends Cardiovasc. Med. 4:223-230.
4. Brown, M.S., and Goldstein, J.L. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52:223-261.
5. Sliskovic, D.R., and White, A.D. 1991. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol. Sci. 12:194-199.
6. Krause, B.R., and Bocan, T.M.A. 1995. ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals. In Inflammation, Mediators and pathways. R.R. Ruffolo, Jr. and M.A. Hollinger, editors. CRC Press, Boca Raton, FL. 173-198.
7. Matsuda, K. 1994. ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms. Med. Res. Rev. 14:271-305.
8. Krause, B.R., Sliskovic, D.R., and Bocan, T.M.A. 1995. Emerging therapies in atherosclerosis. Expert Opinion on Investigational Drugs. 4:353-387.
9. Lee, H.T., et al. 1996. Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. C1-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesrerol-supplemented diets. J. Med. Chem. 39:5031-5034.
10. Wrenn, S.M., Jr., Parks, J.S., Immermann, F.W., and Rudel, L.L. 1995. ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys. J. Lipid Res. 36:1199-1210.
11. Asami, Y., et al. 1998. HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits. Life Sci. 62:1055-1063.
12. Bocan, T.M.A., et al. 1991. Comparison of C1-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation. Arterioscler. Thromb. 11:1830-1843.
13. Matsuo, M., et al. 1995. Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Biochim. Biophys. Acta. 1259:254-260.
14. Nicolosi, R.J., Wilson, T.A., and Krause, B.R. 1998. The ACAT inhibitor, C1-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis. 137:77-85.
15. Chang, C.C.Y., Huh, H.Y., Cadigan, K.M., and Chang, T.Y., 1993. Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J. Biol. Chem. 268:20747-20755.
16. Cases, S., et al. 1998. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization. J. Biol. Chem. 273:26755-26764.
17. Anderson, R.A., et al. 1998. Identification of a form of Acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J. Biol. Chem. 273:26747-26754.
18. Oelkers, P., et al. 1998. Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes. J. Biol. Chem. 273:26765-26771.
19. Meiner, V., et al. 1997. Tissue expression studies of mouse acyl CoA:cholesterol acyltransferase gene (Acact): findings supporting the existence of multiple cholesterol esterification enzymes in mice. J. Lipid Res. 38:1928-1933.
20. Miyazaki, A., et al. 1998. Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. Arterioscler. Thromb. Vasc. Biol. 18:1568-1574.
21. Meiner, V.L., et al. 1996. Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterification enzymes in mammals. Proc. Natl. Acad. Sci. USA. 93:14041-14046.
22. Piedrahita, J.A., et al. 1992. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA. 89:4471-4475.
23. Gaw, A., Mancini, F.P., and Ishibashi, S. 1995. Rapid genotyping of low density lipoprorein receptor knockout mice using a polymerase chain reaction technique. Lab. Anim. 29:447-449.
24. Schwarz, M., Russell, D.W., Dietschy, J.M., and Turley, S.D. 1998. Marked reduction in bile acid synthesis in cholesterol 7α-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J. Lipid Res. 39:1833-1843.
25. Fazio, S., et al. 1997. Leukocyte low density lipoprotein receptor (LDL-R) does not contribute to LDL clearance in vivo: bone marrow transplantation studies in the mouse. J. Lipid Res. 38:391-400.
26. Lindeskog, G.R., and Gustafson, A. 1972. Serum lipoprorein deficiency in diffuse "normolipemic" plane xanthoma. Arch. Dermatol. 106:529-532.
27. Williford, P.M., White, W.L., Jorizzo, J.L., and Greer, K. 1993. The spectrum of normolipemic plane xanthoma. Am. J. Dermatopathol. 15:572-575.
28. van Ree, J.H., et al. 1995. Atypical xanthomatosis in apolipoprotein E-deficient mice after cholesterol feeding. Atherosclerosis. 112:237-243.
29. Feingold, K.R., et al. 1995. Apolipoprotein I: deficiency leads to cutaneous foam cell formation in mice. J. Invest. Dermatol. 104:246-250.
30. Warner, G.J., et al. 1995. Cell toxicity induced by inhibition of acyl coenzyme A:cholesrerol acyltransferase and accumulation of unesterified cholesterol. J. Biol. Chem. 270:5772-5778.
31. Kellner-Weibel, G., et al. 1998. Effects of intracellular free cholesterol accumulation on macrophage viability. A model for foam cell death. Arterioscler. Thromb. Vasc. Biol. 18:423-431.
32. Tabas, I. 1997. Free cholesterol-induced cytotoxicity: a possible contributing factor to macrophage foam cell necrosis in advanced atherosclerotic lesions. Trends Cardiovasc. Med. 7:256-263.
33. Hasselbacher, P., and Hahn, J.L. 1980. Activation of the alternative pathway of complement by microcrystalline cholesterol. Atherosclerosis. 37:239-245.
34. Libby, P., et al. 1996. Macrophages and atherosclerotic plaque stability. Curr. Opin. Lipidol. 7:330-335.